Healthcare ❯ Pharmaceutical Industry
Innovation Biotechnology Technology Investments Chronic Diseases Clinical Trials
The decision answers potential Trump administration tariffs by bolstering U.S. manufacturing to help meet the company’s goal of half its revenue from America by 2030.
